The global medical contrast agent market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing number of cardiovascular disorders, neurological disorders, and cancer cases globally. The increasing prevalence of these diseases has led to an increase in the demand for contrast agents in various applications such as cardiology, neurology, gastroenterology, oncology and nephrology.
The global medical contrast agent market by type is segmented into bariubased contrast media (BCM), iodinated contrast media (ICM), gadolinium-based contrast media (GBCM) and microbubble-based contrast media (MBCM). BCMs are used for imaging purposes in various applications such as cardiology, neurology and gastroenterology. ICMs are used for imaging purposes in various applications such as cardiology and neurology while GBCMs are used for imaging purposes in various applications such as oncology and nephrology. MBCMs are used for imaging purposes in various applications such as cardiology and neurology while they also have therapeutic properties which can be utilized by physicians during treatment procedures like angioplasty or stent placement procedures.
-The global medical contrast agent market is expected to grow at a CAGR of 5.5% from 2017 to 2022.
-The growth of the global medical contrast agent market is driven by factors such as increasing prevalence of chronic diseases, rising demand for minimally invasive procedures, and growing number of hospitals and healthcare facilities.
-Increasing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular disease are driving the growth in the global medical contrast agent market. The increase in incidence rates for these diseases has led to an increased need for diagnostic imaging procedures which in turn has led to an increase in demand for medical contrast agents.
Industry Growth Insights published a new data on “Medical Contrast Agent Market”. The research report is titled “Medical Contrast Agent Market research by Types (Barium-based Contrast Media, Iodinated Contrast Media, Gadolinium-based Contrast Media, Microbubble Contrast Media), By Applications (Cardiovascular Disorders, Neurological Disorders, Gastrointestinal Disorders, Cancer, Nephrological Disorders, Musculoskeletal Disorders, Other Applications), By Players/Companies GE Healthcare, Bayer, Bracco Imaging, Guerbet Group, Lantheus Medical Imaging, Nanopet Pharma, CMC Contrast, Daiichi Sankyo, Subhra Pharma Private, Spago Nanomedical”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Medical Contrast Agent Market Research Report
By Type
Barium-based Contrast Media, Iodinated Contrast Media, Gadolinium-based Contrast Media, Microbubble Contrast Media
By Application
Cardiovascular Disorders, Neurological Disorders, Gastrointestinal Disorders, Cancer, Nephrological Disorders, Musculoskeletal Disorders, Other Applications
By Companies
GE Healthcare, Bayer, Bracco Imaging, Guerbet Group, Lantheus Medical Imaging, Nanopet Pharma, CMC Contrast, Daiichi Sankyo, Subhra Pharma Private, Spago Nanomedical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
245
Number of Tables & Figures
172
Customization Available
Yes, the report can be customized as per your need.
Global Medical Contrast Agent Market Report Segments:
The global Medical Contrast Agent market is segmented on the basis of:
Types
Barium-based Contrast Media, Iodinated Contrast Media, Gadolinium-based Contrast Media, Microbubble Contrast Media
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cardiovascular Disorders, Neurological Disorders, Gastrointestinal Disorders, Cancer, Nephrological Disorders, Musculoskeletal Disorders, Other Applications
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GE Healthcare
- Bayer
- Bracco Imaging
- Guerbet Group
- Lantheus Medical Imaging
- Nanopet Pharma
- CMC Contrast
- Daiichi Sankyo
- Subhra Pharma Private
- Spago Nanomedical
Highlights of The Medical Contrast Agent Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Barium-based Contrast Media
- Iodinated Contrast Media
- Gadolinium-based Contrast Media
- Microbubble Contrast Media
- By Application:
- Cardiovascular Disorders
- Neurological Disorders
- Gastrointestinal Disorders
- Cancer
- Nephrological Disorders
- Musculoskeletal Disorders
- Other Applications
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Medical Contrast Agent Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Medical contrast agent is a substance that helps doctors see inside the body. It is often used during surgery to help surgeons see blood vessels and other structures.
Some of the major players in the medical contrast agent market are GE Healthcare, Bayer, Bracco Imaging, Guerbet Group, Lantheus Medical Imaging, Nanopet Pharma, CMC Contrast, Daiichi Sankyo, Subhra Pharma Private, Spago Nanomedical.
The medical contrast agent market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Medical Contrast Agent Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Medical Contrast Agent Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Medical Contrast Agent Market - Supply Chain
4.5. Global Medical Contrast Agent Market Forecast
4.5.1. Medical Contrast Agent Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Medical Contrast Agent Market Size (000 Units) and Y-o-Y Growth
4.5.3. Medical Contrast Agent Market Absolute $ Opportunity
5. Global Medical Contrast Agent Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Medical Contrast Agent Market Size and Volume Forecast by Type
5.3.1. Barium-based Contrast Media
5.3.2. Iodinated Contrast Media
5.3.3. Gadolinium-based Contrast Media
5.3.4. Microbubble Contrast Media
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Medical Contrast Agent Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Medical Contrast Agent Market Size and Volume Forecast by Application
6.3.1. Cardiovascular Disorders
6.3.2. Neurological Disorders
6.3.3. Gastrointestinal Disorders
6.3.4. Cancer
6.3.5. Nephrological Disorders
6.3.6. Musculoskeletal Disorders
6.3.7. Other Applications
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Medical Contrast Agent Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Medical Contrast Agent Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Medical Contrast Agent Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Medical Contrast Agent Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Medical Contrast Agent Demand Share Forecast, 2019-2029
9. North America Medical Contrast Agent Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Medical Contrast Agent Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Medical Contrast Agent Market Size and Volume Forecast by Application
9.4.1. Cardiovascular Disorders
9.4.2. Neurological Disorders
9.4.3. Gastrointestinal Disorders
9.4.4. Cancer
9.4.5. Nephrological Disorders
9.4.6. Musculoskeletal Disorders
9.4.7. Other Applications
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Medical Contrast Agent Market Size and Volume Forecast by Type
9.7.1. Barium-based Contrast Media
9.7.2. Iodinated Contrast Media
9.7.3. Gadolinium-based Contrast Media
9.7.4. Microbubble Contrast Media
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Medical Contrast Agent Demand Share Forecast, 2019-2029
10. Latin America Medical Contrast Agent Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Medical Contrast Agent Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Medical Contrast Agent Market Size and Volume Forecast by Application
10.4.1. Cardiovascular Disorders
10.4.2. Neurological Disorders
10.4.3. Gastrointestinal Disorders
10.4.4. Cancer
10.4.5. Nephrological Disorders
10.4.6. Musculoskeletal Disorders
10.4.7. Other Applications
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Medical Contrast Agent Market Size and Volume Forecast by Type
10.7.1. Barium-based Contrast Media
10.7.2. Iodinated Contrast Media
10.7.3. Gadolinium-based Contrast Media
10.7.4. Microbubble Contrast Media
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Medical Contrast Agent Demand Share Forecast, 2019-2029
11. Europe Medical Contrast Agent Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Medical Contrast Agent Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Medical Contrast Agent Market Size and Volume Forecast by Application
11.4.1. Cardiovascular Disorders
11.4.2. Neurological Disorders
11.4.3. Gastrointestinal Disorders
11.4.4. Cancer
11.4.5. Nephrological Disorders
11.4.6. Musculoskeletal Disorders
11.4.7. Other Applications
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Medical Contrast Agent Market Size and Volume Forecast by ype
11.7.1. Barium-based Contrast Media
11.7.2. Iodinated Contrast Media
11.7.3. Gadolinium-based Contrast Media
11.7.4. Microbubble Contrast Media
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Medical Contrast Agent Demand Share, 2019-2029
12. Asia Pacific Medical Contrast Agent Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Medical Contrast Agent Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Medical Contrast Agent Market Size and Volume Forecast by Application
12.4.1. Cardiovascular Disorders
12.4.2. Neurological Disorders
12.4.3. Gastrointestinal Disorders
12.4.4. Cancer
12.4.5. Nephrological Disorders
12.4.6. Musculoskeletal Disorders
12.4.7. Other Applications
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Medical Contrast Agent Market Size and Volume Forecast by Type
12.7.1. Barium-based Contrast Media
12.7.2. Iodinated Contrast Media
12.7.3. Gadolinium-based Contrast Media
12.7.4. Microbubble Contrast Media
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Medical Contrast Agent Demand Share, 2019-2029
13. Middle East & Africa Medical Contrast Agent Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Medical Contrast Agent Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Medical Contrast Agent Market Size and Volume Forecast by Application
13.4.1. Cardiovascular Disorders
13.4.2. Neurological Disorders
13.4.3. Gastrointestinal Disorders
13.4.4. Cancer
13.4.5. Nephrological Disorders
13.4.6. Musculoskeletal Disorders
13.4.7. Other Applications
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Medical Contrast Agent Market Size and Volume Forecast by Type
13.7.1. Barium-based Contrast Media
13.7.2. Iodinated Contrast Media
13.7.3. Gadolinium-based Contrast Media
13.7.4. Microbubble Contrast Media
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Medical Contrast Agent Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Medical Contrast Agent Market: Market Share Analysis
14.2. Medical Contrast Agent Distributors and Customers
14.3. Medical Contrast Agent Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. GE Healthcare
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bayer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Bracco Imaging
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Guerbet Group
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Lantheus Medical Imaging
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Nanopet Pharma
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. CMC Contrast
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Daiichi Sankyo
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Subhra Pharma Private
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Spago Nanomedical
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. S
